SFCM
NTLA icon

Seven Fleet Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Seven Fleet Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,500
Closed -$404K – 110
2026
Q1 		$404K Buy
+31,500
New +$401K 0.13% 86

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Seven Fleet Capital Management's NTLA Position: Q2 2026 in Review

Seven Fleet Capital Management sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 31,500 shares — an estimated $404K sold.

Seven Fleet Capital Management first reported a position in NTLA in Q1 2026 and held it in 1 quarter. The position peaked at $404K in Q1 2026. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Seven Fleet Capital Management reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Seven Fleet Capital Management sold 31,500 Intellia Therapeutics shares in Q2 2026, an estimated $404K.
  • Seven Fleet Capital Management first reported a position in Intellia Therapeutics in Q1 2026 and held it in 1 quarter.
  • Seven Fleet Capital Management's Intellia Therapeutics position peaked at $404K in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.